Finvest
INGR Food Ingredients · Ingredients · Staples supplier · Mid cap · Thesis updated June 14, 2026

Argo problems now drive the Ingredion debate

01 Running thesis

The thesis turned on Argo

Ingredion is a useful, real-world business. It turns plants into starches, sweeteners, texturizers, proteins, and other ingredients that many other companies need. The better version of the story is that Texture & Healthful Solutions stays steady, plant-based protein losses shrink, and lower input costs help margins.

That bull case is weaker now. In Q1 2026, Texture & Healthful Solutions operating income rose only 1% to $100 million, and the company said the gain came mainly from foreign exchange. All Other improved to $3 million of operating income, but that segment is too small to carry the company.

The bear case is now clear and specific. F&II U.S./Canada operating income fell 63% to $34 million in Q1 2026. Management tied the drop to production challenges at the Argo facility, plus softer volumes and mix. Until the company gives a clear repair plan and shows better results, this looks like more than a small bump.

Cash flow is the other test. Operating cash flow fell to $33 million in Q1 2026 from $77 million a year earlier. That follows a 2025 cash flow problem, when working capital used $73 million of cash after providing $417 million in 2024. Finn's view is cautious because reported profits are not yet turning into enough cash.

May 2026Q1 2026 made the bear case sharper. F&II U.S./Canada operating income fell 63% to $34 million, with management naming production challenges at the Argo facility, and operating cash flow fell to $33 million.
Feb 2026The FY2025 filing showed that cash conversion had weakened. Operating cash flow fell to $944 million from $1,436 million in 2024, including a $490 million negative swing from working capital.
Nov 2025Q3 2025 showed the cash problem was lasting longer than expected. Year-to-date operating cash flow fell to $539 million from $1 billion, and F&II U.S./Canada operating income declined 18%.
Aug 2025Q2 2025 kept the margin story alive, but added two major worries. Operating cash flow stayed weak because of accounts receivable, and F&II U.S./Canada operating income fell 18%.
May 2025Q1 2025 strengthened the original bull case, as gross margin rose to 26% from 22% and T&HS operating income rose 34%. The first cash flow warning also appeared as operating cash flow fell to $77 million from $209 million.
Feb 2025The FY2024 filing reset the segment structure and added new risks from weight-loss drugs and sustainability reporting costs. The balance sheet looked stronger, but sales were down 9% for 2024.
Nov 2024Initial view: Ingredion was a plant-based ingredients company with margin help from lower input costs. The main debate was whether margin gains could offset lower sales and divestiture pressure.
02 Business model

Plants in, ingredients out

Ingredion buys raw materials such as grains, fruits, vegetables, and other plant-based inputs. It processes them into ingredients, then sells those ingredients to food, beverage, animal nutrition, brewing, and industrial customers.

The model can work well when plants run smoothly and raw material costs are managed. Lower corn and input costs helped margins in 2024 and parts of 2025. The company also has higher-value products in Texture & Healthful Solutions, where customers pay for texture, nutrition, and product performance, not only bulk calories.

The model breaks when factories stumble or working capital grows. A plant issue can lower output, raise costs, and hurt mix. Receivables and inventory can also trap cash, even if the income statement still shows profit. That is why Argo and cash conversion are the two biggest watch items now.

03 Product portfolio

What Ingredion sells

Growth engine

Texture and healthful ingredients

These ingredients help food and drink makers change texture, mouthfeel, and nutrition. This is the higher-value part of the portfolio, but Q1 2026 growth was only 1% in operating income.

Cash cow

Food and industrial ingredients in LATAM

This segment sells core ingredients across Latin America. Q1 2026 net sales were $579 million, but operating income fell 9% because of Mexico currency impacts and softer volumes.

Steady

Food and industrial ingredients in U.S./Canada

This should be a core profit base, but it is now the biggest problem. Q1 2026 operating income fell 63% to $34 million due to Argo facility production challenges and softer volumes and mix.

Option

Plant-based proteins

Plant-based protein sits in All Other and is still small. The segment moved to $3 million of operating income in Q1 2026, which suggests some improvement, but not enough to offset the U.S./Canada drop.

Steady

Industrial and brewing ingredients

Ingredion also serves brewing and industrial markets. These uses broaden demand beyond packaged food, but they can still be hit by weaker industrial volumes.

04 Business segments

Q1 2026 mix

Texture & Healthful Solutions34%modest
F&II LATAM32%declining
F&II U.S./Canada27%declining
All Other7%modest

Segment shares use Q1 2026 net sales: $617 million for T&HS, $579 million for F&II LATAM, $475 million for F&II U.S./Canada, and $121 million for All Other. This is a quarterly mix, so it can shift with crop costs, currencies, volumes, and plant downtime.

05 Risk factors

What could break the case

Argo facility drag lasts too long

High impact · High odds

The Argo facility is now the named source of the production challenge in F&II U.S./Canada. That segment's operating income fell 63% to $34 million in Q1 2026. If the issue needs major spending or takes many quarters to fix, earnings could stay weak.

We watchQ2 2026 F&II U.S./Canada operating income, management's repair timeline, and any new capital spending tied to Argo.

Cash flow does not recover

High impact · High odds

Operating cash flow fell to $33 million in Q1 2026 from $77 million a year earlier. In 2025, working capital used $73 million of cash, compared with $417 million provided in 2024. If receivables or inventory keep rising, reported profit may overstate the cash the business can return to owners.

We watchOperating cash flow, inventory, receivables, and the working capital line in each quarterly filing.

T&HS cannot carry the company

Medium impact · Medium odds

Texture & Healthful Solutions is the better-quality segment in the story. But in Q1 2026, operating income rose only 1% to $100 million, mainly due to foreign exchange. If growth stays this slow, it cannot offset weakness in the larger F&II businesses.

We watchT&HS volume growth, operating income growth, and whether gains come from real demand instead of currency.

Food demand shifts from weight-loss drugs

Medium impact · Medium odds

Ingredion has flagged weight-loss drugs as a consumer preference risk. If these medicines reduce total food and drink consumption over time, demand for some ingredients could soften. The risk is slow moving, but it matters because Ingredion sells into many food and beverage categories.

We watchPackaged food volume trends, beverage demand, and company comments about GLP-1 or weight-loss drug effects.

Input costs and currencies move against margins

Medium impact · Medium odds

Ingredion's results can swing with corn and other raw material costs, energy, freight, and currencies. LATAM operating income fell 9% in Q1 2026, with Mexico currency impacts and softer volumes called out. Hedging can help, but it does not remove the risk.

We watchGross margin, Mexico currency commentary, raw material cost pass-through, and LATAM operating income.